…in the UK. The Covid-19 pandemic may now be declared officially over, but the boost in trust that the sector enjoyed as a result of its role in combating it…
…2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can this company make age a thing of the past?” With Covid-19 taking so much of the drug discovery…
…emergence of the novel coronavirus and the crisis it caused. In this episode, Kelland shares what she means by the ‘next pandemic’, the lessons learnt from the Covid-19 pandemic, and…
The term ‘PCR’ has been on everybody’s lips since the outbreak of the Covid-19 pandemic, but only laboratory professionals know how difficult it can be to achieve success with this…
…will begin soon.” Additional limitations include relatively short follow-up time and some setbacks, including cancer vaccine shortage, during the Covid-19 pandemic. According to Sullivan, a technical limitation of the neoantigen…
…be ready by 2030, and a new treatment for long Covid fatigue could be available soon. There is also new hope for sepsis treatment and for preventing cardiovascular disease in…
…from long Covid fatigue may be in sight. Our approach allows us to target several pathways that are disrupted in long Covid, and our previous experience with AXA1125 suggests that…
…12 to 18 months owing to the success of the Covid-19 mRNA jab1. Dr Paul Burton, the Chief Medical Officer of Moderna, told the Guardian: “We will have that vaccine…
…drug discovery sector, whether AI can discover new medicines, and why post-Covid-19 cognitive impairment is a new target for drug development. Exclusive Cancer Research Guide This issue contains an exclusive…
Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement…
…Strateos and the Covid-19 pandemic have impacted the future of the lab. You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. Listen here:…
…receive £10 million ($12.2 million) funding. Flexible and agile regulation Marc Bailey, MHRA Chief Science and Innovation Officer, said: “Our world-first Covid-19 approvals showed how important it is to ensure…
New findings suggest that the SARS-CoV-2 virus damages an important immune-cell response. The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower…
